Dermata Therapeutics, Inc. announced the termination of its License Agreement with Villani, effective 90 days after notice on November 17, 2025, due to a strategic shift to focus on over-the-counter skincare products, eliminating potential payments of up to $40.5 million in milestones and royalties.